Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Ganetespib (Primary) ; Gemtuzumab ozogamicin (Primary) ; Midostaurin (Primary) ; Fludarabine
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms AML-19; AML19
- 31 Aug 2018 Biomarkers information updated
- 28 Jan 2016 Accrual to date is 0% as per United Kingdom Clinical Research Network record.
- 28 Jan 2016 Planned End Date changed from 1 Jan 2021 to 1 Nov 2021 as per United Kingdom Clinical Research Network record.